These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8315574)

  • 1. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.
    St Clair MH; Hartigan PM; Andrews JC; Vavro CL; Simberkoff MS; Hamilton JD
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):891-7. PubMed ID: 8315574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.
    Koot M; Keet IP; Vos AH; de Goede RE; Roos MT; Coutinho RA; Miedema F; Schellekens PT; Tersmette M
    Ann Intern Med; 1993 May; 118(9):681-8. PubMed ID: 8096374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
    AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.
    Leal M; Torres Y; Medrano FJ; Rey C; Caruz A; Sánchez-Quijano A; Lissen E
    Eur J Clin Invest; 1996 Oct; 26(10):923-8. PubMed ID: 8911867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral phenotype, antiretroviral resistance and clinical evolution in human immunodeficiency virus-infected children.
    Mellado MJ; Cilleruelo MJ; Ortiz M; Villota J; García M; Perez-Jurado ML; Barreiro G; Martín-Fontelos P; Bernal A
    Pediatr Infect Dis J; 1997 Nov; 16(11):1032-7. PubMed ID: 9384335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children.
    Spencer LT; Ogino MT; Dankner WM; Spector SA
    J Infect Dis; 1994 Mar; 169(3):491-5. PubMed ID: 7908924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
    D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD
    Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
    Koot M; Schellekens PT; Mulder JW; Lange JM; Roos MT; Coutinho RA; Tersmette M; Miedema F
    J Infect Dis; 1993 Sep; 168(3):733-6. PubMed ID: 8102631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue.
    McGavin CH; Land SA; Sebire KL; Hooker DJ; Gurusinghe AD; Birch CJ
    AIDS; 1996 Jan; 10(1):47-53. PubMed ID: 8924251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine.
    Torres Y; Leal M; Rey C; Medrano FJ; Sánchez-Quijano A; Lissen E
    Eur J Clin Microbiol Infect Dis; 1996 Apr; 15(4):324-7. PubMed ID: 8781884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury.
    Pratt RD; Shapiro JF; McKinney N; Kwok S; Spector SA
    J Infect Dis; 1995 Sep; 172(3):851-4. PubMed ID: 7658081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
    J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine resistance of human immunodeficiency virus.
    Richman DD
    Rev Infect Dis; 1990; 12 Suppl 5():S507-10; discussion S510-2. PubMed ID: 2201072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.
    Richman DD; Bozzette SA
    J Infect Dis; 1994 May; 169(5):968-74. PubMed ID: 7909549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.
    Land S; McGavin C; Lucas R; Birch C
    J Infect Dis; 1992 Nov; 166(5):1139-42. PubMed ID: 1402026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
    Tersmette M; Lange JM; de Goede RE; de Wolf F; Eeftink-Schattenkerk JK; Schellekens PT; Coutinho RA; Huisman JG; Goudsmit J; Miedema F
    Lancet; 1989 May; 1(8645):983-5. PubMed ID: 2565516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.